BM213 is a peptide-like research scaffold containing tailored hydrophobic, aromatic, and polar residues that form defined recognition surfaces. Sequence composition promotes stable secondary structure under physiological conditions. Researchers use it to interrogate protein-ligand contacts and binding thermodynamics. Applications include ligand-discovery screening, structural biophysics, and SAR evaluation.
CAT No: R2756
Synonyms/Alias:BM213; CHEMBL5071478; 2891606-02-1; BDBM50587341; MS-31708; HY-145237; CS-0370230; F83816
BM213 is a synthetic small molecule compound recognized for its potent activity as an efflux pump inhibitor, particularly targeting resistance-nodulation-division (RND) family transporters in Gram-negative bacteria. Structurally distinct from antibiotics, it plays a significant role in antimicrobial resistance research by modulating the function of multidrug efflux pumps. BM213 has garnered attention in the biochemical and microbiological research communities for its ability to restore the efficacy of various antibacterial agents, making it a valuable tool for elucidating resistance mechanisms and exploring novel approaches to combat multidrug-resistant pathogens.
Antimicrobial resistance studies: In the context of antimicrobial resistance research, BM213 is widely employed to investigate the role of efflux pumps in bacterial survival under antibiotic stress. By selectively inhibiting RND-type efflux transporters, it enables researchers to delineate the contribution of active efflux to multidrug resistance phenotypes. The compound facilitates comparative studies where the impact of efflux inhibition on antibiotic susceptibility can be systematically assessed, providing insights into resistance mechanisms and informing the development of more effective antibacterial strategies.
Drug synergy evaluation: BM213 is frequently used in synergy assays to assess the combinatorial effects of efflux pump inhibition with conventional antibiotics. In such experiments, the compound is co-administered with antimicrobial agents to determine whether blocking efflux transporters can enhance intracellular drug accumulation and potentiate antibacterial activity. These studies are crucial for identifying antibiotic-adjuvant combinations that may overcome resistance barriers, supporting the rational design of combination therapies for difficult-to-treat infections.
Efflux pump characterization: The compound serves as a functional probe in biochemical and genetic studies aimed at characterizing the specificity, kinetics, and regulation of RND family efflux systems. By modulating transporter activity, BM213 helps dissect the substrate profiles and transport mechanisms of individual efflux pumps. Researchers utilize it to validate transporter gene knockouts, analyze compensatory pathways, and elucidate the molecular determinants of efflux-mediated resistance, thereby advancing the fundamental understanding of bacterial membrane transport processes.
High-throughput screening applications: BM213 is incorporated into high-throughput screening platforms to identify novel efflux pump inhibitors or to evaluate compound libraries for efflux-modulating activity. Its well-characterized inhibitory profile enables its use as a reference or positive control compound in assay development, ensuring reliable benchmarking of new chemical entities. These screening efforts are pivotal for expanding the repertoire of efflux-targeting molecules and for accelerating the discovery of adjuvant candidates with clinical potential.
Mechanistic studies in bacterial physiology: Researchers leverage BM213 to probe the physiological consequences of efflux pump inhibition beyond antibiotic susceptibility, such as impacts on cellular homeostasis, metabolic adaptation, and stress responses. By transiently blocking efflux activity, it is possible to examine changes in intracellular metabolite concentrations, membrane integrity, and gene expression patterns, contributing to a holistic understanding of bacterial adaptation mechanisms. Such studies inform the broader implications of efflux modulation in microbial ecology and pathogenesis.
1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More